Andere talen Sangamo Therapeutics, Inc.

Aandelen

SGMO

US8006771062

Geschatte realtime Cboe BZX Andere beurzen 16:04:56 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,513 ^USD	+1,99%		+0,63%	-5,26%

22/03	Sangamo Therapeutics prijst $24 miljoen Geregistreerd Direct Aanbod	MT
14/03	Sangamo Therapeutics duwt neurologieprogramma's richting klinische ontwikkeling, zegt Wedbush	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data from Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting	23/04
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)	22/04
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	25/03
Sangamo Therapeutics Prices $24 Million Registered Direct Offering	22/03
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	22/03
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	14/03
Sangamo: Q4 Earnings Snapshot	13/03
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	13/03
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs	13/03
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023	13/03
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps	13/03
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast	12/03
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease	12/02
Sangamo Therapeutics Says Early Phase 1/2 Data Shows 'Durable' Safety, Efficacy of Fabry Disease Drug Candidate	06/02
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile	06/02
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920	05/02
Vaxcyte Names Chief People Officer	16/01
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) dropped from NASDAQ Biotechnology Index	15/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sangamo Therapeutics, Inc.

Aandelen

SGMO

US8006771062

Andere talen

Filters